This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Examine whether treatment of individuals with impaired glucose tolerance with pioglitazone can prevent or delay the development of type 2 diabetes mellitus. Secondary aims will include changes in glucose control, insulin secretion, insulin sensitivity, blood pressure, body fat and markers of cardiovascular morbidity.
Showing the most recent 10 out of 1825 publications